An experimental Alzheimer’s drug made by Eisai Co. and Biogen Inc. slowed the rate of cognitive decline among patients in the early stages of the illness in a large study, improving its chances of future approval.
Recommended Stories
Print subscriber? Click here to login/register your account
Digital subscriber? Click here to login/register your account.